During a meeting with the investment community today, Bristol-Myers
Squibb Company (NYSE:BMY) will provide a comprehensive business
overview, highlight positive pipeline developments and provide 2013
minimum non-GAAP earnings per share guidance.
“I am fully confident in our ability to deliver on our three major
strategic imperatives -- driving our performance in the next few years,
improving our earnings base in 2013 and sustaining growth in 2014 and
beyond”
“In December 2007, we outlined a strategy and a set of deliverables.
Since then we have delivered consistently by executing relentlessly on
our BioPharma strategy, meeting our commitments and sustaining excellent
operational and financial performance,” said James
M. Cornelius, chairman and chief executive officer. “We have
fundamentally differentiated ourselves from our peers as a focused
biopharmaceutical company that is well-positioned to deliver on the
promise of our pipeline.”
The company expects 2013 non-GAAP earnings per share to be, at minimum,
$1.95, setting a base for sustained growth expected to begin in 2014.
The company also expects 2013 to be the first full year of impact from
the loss of Plavix patent exclusivity in the U.S.
During today’s meeting, the company also plans to provide an update on
its successful transformation into a next-generation BioPharma leader,
outline key strategic imperatives and the company’s overall outlook.
“I am fully confident in our ability to deliver on our three major
strategic imperatives -- driving our performance in the next few years,
improving our earnings base in 2013 and sustaining growth in 2014 and
beyond,” said Lamberto
Andreotti, president and chief operating officer. “We have important
strategic, operational and financial levers which will allow us to fully
realize our potential as a BioPharma leader, and to deliver on our
near-term and long-term growth opportunities.”
INVESTMENT COMMUNITY MEETING HIGHLIGHTS
Bristol-Myers Squibb management will review key accomplishments as part
of its BioPharma transformation, highlight strategic imperatives that
will drive near-term growth and provide an in-depth overview of the
company’s late-stage and early development pipeline, in particular the
company’s progress in Alzheimer’s disease and hepatitis C.
Management will also provide an overview of its plans to execute its key
imperatives by driving top-line revenue growth from current and
potentially new products, delivering on the pipeline, building on
progress made in productivity initiatives and the use of cash, working
capital and other financial tools to invest in the future.